| Abstrakt: |
A recent study conducted by the University of Verona in Italy has identified potential blood cell-based biomarkers for predicting responses to immune checkpoint inhibitor (ICI) monotherapy in patients with non-small cell lung cancer (NSCLC). The researchers evaluated various blood-based biomarkers and found that low counts of plasmacytoid dendritic cells (pDCs), slan+-monocytes, and natural killer cells, as well as a high lung immune prognostic index (LIPI) score and elevated PD-L1 expression levels on type 1 conventional dendritic cells (cDC1s), were independently associated with a negative response to ICI therapy in NSCLC patients. These findings suggest that evaluating innate immune cell numbers and phenotypes may serve as promising predictive biomarkers for ICI monotherapy in NSCLC patients. [Extracted from the article] |
